Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Björklund(Karolinska Institutet), Karl‐Johan Malmberg(Karolinska University Hospital), Jeffrey S. Miller(Science Museum of Minnesota), Ebba Sohlberg(Karolinska University Hospital), Emma Watz(Karolinska University Hospital), Monika Klimkowska(Karolinska University Hospital), Mattias Carlsten(Karolinska University Hospital), Marzia Palma(Karolinska University Hospital), Lotta Hansson(Karolinska Institutet), Björn E. Wahlin(Karolinska University Hospital), Per Ljungman(Karolinska University Hospital), Eva Hellström-Lindberg(Karolinska University Hospital), Trevor Clancy(Inholland University of Applied Sciences), Lisa L. Liu(Karolinska University Hospital), Hans‐Gustaf Ljunggren(Karolinska Institutet), Sarah Cooley(Palmetto Hematology Oncology), Mohsen Karimi(Karolinska Institutet), Pontus Blomberg(Karolinska University Hospital), Marie Schaffer(Karolinska University Hospital), Kristina Wikström(Karolinska University Hospital)
Cited by 195
Related Papers
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
|Journal of Clinical Investigation|2017|311